TuftsCSDD-Logo-Color.jpg
Number of Monoclonal Antibody Products in Development Continues to Increase, According to Tufts Center for the Study of Drug Development
08 nov. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 8, 2011) - Developers are steadily increasing the number of monoclonal antibody products -- known as mAbs -- for which they are initiating clinical studies, extending...
TuftsCSDD-Logo-Color.jpg
Drug Companies Are Using Innovative Partnerships to Spur Development, According to Tufts Center for the Study of Drug Development
06 oct. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Oct 6, 2011) - Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative...
TuftsCSDD-Logo-Color.jpg
Majority of Clinical Trial Protocols Are Amended, but One-Third of Those Changes Are Avoidable, According to Tufts Center for the Study of Drug Development
13 sept. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Sep 13, 2011) - Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been...
TuftsCSDD-Logo-Color.jpg
Growing Regulatory Requirements Worldwide Challenge Drug Developers, According to Tufts Center for the Study of Drug Development
09 août 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Aug 9, 2011) - As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory...
TuftsCSDD-Logo-Color.jpg
Lack of Clinically Useful Diagnostics Hinders Growth in Personalized Medicines, According to Tufts Center for the Study of Drug Development
19 juil. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jul 19, 2011) - Lack of evidence that links diagnostic tests to health outcomes has led payers in the United States to be skeptical about the clinical usefulness of those...
TuftsCSDD-Logo-Color.jpg
Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade, According to Tufts Center for the Study of Drug Development
10 mai 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 10, 2011) - U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of...
TuftsCSDD-Logo-Color.jpg
Drug Developers Actively Improving Efficiency of Clinical Trials, According to Tufts Center for the Study of Drug Development
26 avr. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Apr 26, 2011) - Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with...
TuftsCSDD-Logo-Color.jpg
U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily, According to Tufts Center for the Study of Drug Development
08 mars 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 8, 2011) - New or modified indication approvals for existing prescription drugs have steadily increased in the United States since the late 1990s, according to an...
TuftsCSDD-Logo-Color.jpg
Translational Science Expected to Play a Growing Role in Creating New Drugs, According to Tufts Center for the Study of Drug Development
27 janv. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2011) - To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to...
TuftsCSDD-Logo-Color.jpg
U.S. Healthcare Stakeholders Uncertain About Benefits of Risk Evaluation Program, According to Tufts Center for the Study of Drug Development
12 janv. 2011 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 12, 2011) - Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about...